Compare ARCB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCB | TARS |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1994 | 2020 |
| Metric | ARCB | TARS |
|---|---|---|
| Price | $133.97 | $77.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $167.15 | $103.44 |
| AVG Volume (30 Days) | 222.6K | ★ 830.6K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $1,657,864,000.00 | $451,360,000.00 |
| Revenue This Year | $12.44 | $64.28 |
| Revenue Next Year | $7.93 | $26.15 |
| P/E Ratio | $82.15 | ★ N/A |
| Revenue Growth | 12.56 | ★ 146.71 |
| 52 Week Low | $59.43 | $53.89 |
| 52 Week High | $176.69 | $91.53 |
| Indicator | ARCB | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 59.85 |
| Support Level | $133.90 | $67.49 |
| Resistance Level | $144.77 | $80.00 |
| Average True Range (ATR) | 5.70 | 3.69 |
| MACD | 0.72 | 0.86 |
| Stochastic Oscillator | 57.35 | 94.18 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.